• Mabwell proposed a new board lineup at a June 18, 2026 EGM, setting up leadership continuity under chairman and general manager Liu Datao.
• Executive director slate includes Liu, founder Tang Chunshan, R&D president Wu Hai, CFO Hua Jun; Gui Xun to be chosen separately as employee director.
• Retirements planned for Hu Huiguo, Wu Yufeng, Xu Qing, Zhao Qian once new directors are elected; Hu stays as deputy general manager.
• Wu Hai previously held senior R&D roles at Amgen, Trellis Bioscience; served at Junshi as deputy general manager and director.
• Hua Jun previously worked in finance roles at GE, Johnson & Johnson, Roche, Hutchison MediPharma; later ran finance and procurement at Henlius.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mabwell (Shanghai) Bioscience Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260531-12178633), on May 31, 2026, and is solely responsible for the information contained therein.